The novel hypoxic cell radiosensitizer, TX-1877 has antitumor activity through suppression of angiogenesis and inhibits liver metastasis on xenograft model of pancreatic cancer

Cancer Letters

Volumn 272, Issue 2, 2008, Pages 325-335

  Miyake, Kotaro ^a   Shimada, Mitsuo ^a   Nishioka, Masanori ^a   Sugimoto, Koji ^a   Batmunkh, Erdenebulgan ^a   Uto, Yoshihiro ^a   Nagasawa, Hideko ^b   Hori, Hitoshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Antiangiogenesis; Antimetastasis; Hypoxic cell; Radiosensitizer; TX 1877

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GELATINASE B; INTERLEUKIN 8; RADIOSENSITIZING AGENT; TX 1877; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; METASTASIS INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITROIMIDAZOLES; PANCREATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS;

EID: 55949134575     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.020     Document Type: Article

References (46)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 56 (2006) 106-130
2. Bramhall S.R., Allum W.H., Jones A.G., Allwood A., Cummins C., and Neoptolemos J.P. Treatment and survival in 13, 560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br. J. Surg. 82 (1995) 111-115
3. Hendry J.H., and West C.M. Apoptosis and mitotic cell death: their relative contributions to normal-tissue and tumour radiation response. Int. J. Radiat. Biol. 71 (1997) 709-719
4. Cottrill C.P., Bishop K., Walton M.I., and Henk J.M. Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 807-810
5. Huilgol N.G., Chatterjee N., and Mehta A.R. An overview of the initial experience with AK-2123 as a hypoxic cell sensitizer with radiation in the treatment of advanced head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 34 (1996) 1121-1124
6. Lee D.J., Cosmatos D., Marcial V.A., Fu K.K., Rotman M., Cooper J.S., Ortiz H.G., Beitler J.J., Abrams R.A., Curran W.J., et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 32 (1995) 567-576
7. Urtasun R.C., Palmer M., Kinney B., Belch A., Hewitt J., and Hanson J. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study. Int. J. Radiat. Oncol. Biol. Phys. 40 (1998) 337-342
8. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., and Horsman M.R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 6 (2005) 757-764
9. Shibamoto Y., Sugie C., Ito M., and Ogino H. The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs. Expert. Opin. Pharmacother. 5 (2004) 2459-2467
10. Suzuki K., Nagasawa H., Uto Y., Sugimoto Y., Noguchi K., Wakida M., Wierzba K., Terada T., Asao T., Yamada Y., Kitazato K., and Hori H. Napthalimidobenzamide DB-51630: a novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity. Bioorg. Med. Chem. 13 (2005) 4014-4021
11. Coleman C.N., Bump E.A., and Kramer R.A. Chemical modifiers of cancer treatment. J. Clin. Oncol. 6 (1988) 709-733
12. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 19 (2007) 397-417
13. Lee D.J., Pajak T.F., Stetz J., Order S.E., Weissberg J.B., and Fischer J.J. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). Int. J. Radiat. Oncol. Biol. Phys. 16 (1989) 465-470
14. Overgaard J., Hansen H.S., Overgaard M., Bastholt L., Berthelsen A., Specht L., Lindelov B., and Jorgensen K. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the danish head and neck cancer study (DAHANCA) protocol 5-85. Radiother. Oncol. 46 (1998) 135-146
15. Hori H., Murayama C., Mori T., Shibamoto Y., Abe M., Onoyama Y., and Inayama S. KIH-802: 2-nitroimidazole-1-acetohydroxamate as a hypoxic cell radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys. 16 (1989) 1029-1032
16. Nagasawa H., Bando M., Hori H., Satoh T., Tada T., Onoyama Y., and Inayama S. Radiosensitizing, toxicological, and pharmacokinetic properties of hydroxamate analogues of nitroimidazoles as bifunctional radiosensitizers/chemical modifiers. Int. J. Radiat. Oncol. Biol. Phys. 22 (1992) 561-564
17. Bremner J.C. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation. Cancer Metastasis Rev. 12 (1993) 177-193
18. Hori H., Jin C.Z., Kiyono M., Kasai S., Shimamura M., and Inayama S. Design, synthesis, and biological activity of anti-angiogenic hypoxic cell radiosensitizer haloacetylcarbamoyl-2-nitroimidazoles. Bioorg. Med. Chem. 5 (1997) 591-599
19. Jin C.Z., Nagasawa H., Shimamura M., Uto Y., Inayama S., Takeuchi Y., Kirk K.L., and Hori H. Angiogenesis inhibitor TX-1898: syntheses of the enantiomers of sterically diverse haloacetylcarbamoyl-2-nitroimidazole hypoxic cell radiosensitizers. Bioorg. Med. Chem. 12 (2004) 4917-4927
20. Inomata T., Ogawa Y., Nishioka A., Hamada N., Ito S., Kariya S., Yoshida S., Nagasawa H., Hori H., and Inayama S. The immunopotentiation effects of the bifunctional radiosensitizer KIN-806 in comparison with its analogs KIN-804 and KIN-844. Oncol. Rep. 6 (1999) 1209-1212
21. Inomata T., Ogawa Y., Itoh S., Kariya S., Hamada N., Nishioka A., Yoshida S., Nagasawa H., Hori H., and Inayama S. Lung metastasis suppression of the bifunctional new radiosensitizer KIN-806. Int. J. Mol. Med. 4 (1999) 257-260
22. Kasai S., Nagasawa H., Kuwasaka H., Oshodani T., Nishioka A., Ogawa Y., Yoshida S., Inayama S., Inomata T., and Hori H. TX-1877: design, synthesis, and biological activities as a BRM-functional hypoxic cell radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 799-802
23. Oshikawa T., Okamoto M., Ahmed S.U., Furuichi S., Tano T., Sasai A., Kan S., Kasai S., Uto Y., Nagasawa H., Hori H., and Sato M. TX-1877, a bifunctional hypoxic cell radiosensitizer, enhances anticancer host response: immune cell migration and nitric oxide production. Int. J. Cancer 116 (2005) 571-578
24. Kasai S., Nagasawa H., Yamashita M., Masui M., Kuwasaka H., Oshodani T., Uto Y., Inomata T., Oka S., Inayama S., and Hori H. New antimetastatic hypoxic cell radiosensitizers: design, synthesis, and biological activities of 2-nitroimidazole-acetamide, TX-1877, and its analogues. Bioorg. Med. Chem. 9 (2001) 453-464
25. Miyamoto H., Murakami T., Tsuchida K., Sugino H., Miyake H., and Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28 (2004) 38-44
26. Bruns C.J., Harbison M.T., Kuniyasu H., Eue I., and Fidler I.J. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1 (1999) 50-62
27. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 (2001) e45
28. 2 tension measurements. Cancer Res. 51 (1991) 3316-3322
29. 2 tension measurements. Cancer Res. 51 (1991) 6098-6102
30. Vaupel P., and Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9 Suppl 5 (2004) 4-9
31. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., and Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38 (1997) 285-289
32. Brizel D.M., Dodge R.K., Clough R.W., and Dewhirst M.W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53 (1999) 113-117
33. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56 (1996) 4509-4515
34. Vaupel P., Mayer A., and Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol. 381 (2004) 335-354
35. Cairns R., Papandreou I., and Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 4 (2006) 61-70
36. Ranniger K., and Saldino R.M. Arteriographic diagnosis of pancreatic lesions. Radiology 86 (1966) 470-474
37. Yassa N.A., Yang J., Stein S., Johnson M., and Ralls P. Gray-scale and color flow sonography of pancreatic ductal adenocarcinoma. J. Clin. Ultrasound 25 (1997) 473-480
38. Megibow A.J. Pancreatic adenocarcinoma: designing the examination to evaluate the clinical questions. Radiology 183 (1992) 297-303
39. Koong A.C., Mehta V.K., Le Q.T., Fisher G.A., Terris D.J., Brown J.M., Bastidas A.J., and Vierra M. Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 919-922
40. Halberg F.E., Cosmatis D., Gunderson L.L., Noyes R.D., Hanks G.R., Buswell L., Nagorney D.M., and Coleman C.N. RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies. Int. J. Radiat. Oncol. Biol. Phys. 28 (1994) 201-206
41. Shibamoto Y., Ohshio G., Hosotani R., Nishimura Y., Manabe T., Imamura M., and Abe M. A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy. Br. J. Cancer 76 (1997) 1474-1479
42. Tepper J.E., Shipley W.U., Warshaw A.L., Nardi G.L., Wood W.C., and Orlow E.L. The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. J. Clin. Oncol. 5 (1987) 579-584
43. Minchenko A., Salceda S., Bauer T., and Caro J. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell. Mol. Biol. Res. 40 (1994) 35-39
44. Gleadle J.M., Ebert B.L., Firth J.D., and Ratcliffe P.J. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am. J. Physiol. 268 (1995) C1362-C1368
45. Kuwabara K., Ogawa S., Matsumoto M., Koga S., Clauss M., Pinsky D.J., Lyn P., Leavy J., Witte L., Joseph-Silverstein J., et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc. Natl. Acad. Sci. USA 92 (1995) 4606-4610
46. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62